Atelectasis Clinical Trial
Official title:
Evaluation of The MetaNeb® System to Reduce Atelectasis Assessed by Chest X-ray
Verified date | February 2024 |
Source | Baxter Healthcare Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To study objective is to evaluate the impact of use of The MetaNeb® System in clearance of atelectasis, as demonstrated by improvement in chest x-rays. This is a a non-randomized open label study, with all subjects receiving treatment with The MetaNeb® System. Subjects who qualify for enrollment in the study will receive therapy with The MetaNeb® System following the labeled instructions for the device. Details of the treatment including duration and frequency will be defined in treatment procedures.
Status | Completed |
Enrollment | 8 |
Est. completion date | August 17, 2017 |
Est. primary completion date | August 17, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Post-surgical (thoracic, cardiac or abdominal surgery) - Age = 18 years - Significant atelectasis by chest x-ray - Patient meets indication for therapy intervention as defined by Recruitment and Airway Clearance Protocol (Respiratory Department Policy and Procedure) - Signed informed consent Exclusion Criteria: - Cause of atelectasis suspected to be infectious or solid mass - Requirement for mechanical ventilation - Requirement for chronic supplemental oxygen - Hemodynamically unstable, as defined by need for vasopressor therapy - Anticipated need for mechanical ventilation or other poor clinical outcome, unrelated to atelectasis or secretion retention - Contraindication to MetaNeb® therapy (untreated tension pneumothorax) - Inability to perform MetaNeb® therapy using a mouthpiece - Anticipated hospital discharge within 24 hours |
Country | Name | City | State |
---|---|---|---|
United States | Hoag Memorial Hospital Presbyterian | Newport Beach | California |
Lead Sponsor | Collaborator |
---|---|
Hill-Rom |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Chest x-ray score improvement at Day 2 (approximately 48) hours after initiation of therapy with The MetaNeb® System. | Chest x-ray score improvement at Day 2 (approximately 48 hours) after initiation of therapy with The MetaNeb® System. Chest x-rays were scored using the Kelly scoring system to assess the presence of atelectasis on Day 2, after initiation of therapy with The MetaNeb® System. Scores for chest x-rays at Day 2 were compared to the scores for chest x-rays taken at baseline. The Kelly score for each of the chest x-rays was assessed by blinded reader. The baseline chest x-ray for each subject was the qualifying x-ray that determined the presence of significant atelectasis. | Approximately 48 hours post-initiation of therapy with The MetaNeb® System. | |
Secondary | Chest x-ray assessed by Kelly Atelectasis Score at Day 1 (approximately 24 hours) and Day 4 (approximately 96 hours, or at discharge if discharge occurs before Day 4), compared to baseline. | Chest x-ray score improvement at Day 1 (approximately 24 hours) and at Day 4 (approximately 96 hours or at discharge, if discharge occurs before Day 4) after initiation of therapy with The MetaNeb® System. Scored using the Kelly score, as described above, to assess the presence of atelectasis. | Approximately 24 hours and at Day 4, approximately 96 hours, or at discharge if discharge occurs before Day 4 | |
Secondary | Chest x-ray improvement using a comparative scale (comparing baseline, Day 1, Day 2, and Day 4/discharge). | Chest x-ray improvement using a comparative scale after a minimum of forty-eight (48) hours of therapy with The MetaNeb® System. Chest x-ray improvement assessed using comparative scale for baseline, Day 1, Day 2, and Day 4/discharge. Four chest x-rays for each enrolled subject (baseline, Day 1, Day 2, and day 4/discharge), with date and time masked, were sent to the radiologist for comparison. The radiologist ranked the four x-rays as 1, 2, 3, or 4 (1 = least atelectasis, 4 = most atelectasis). | Comparing baseline, Day 1, Day 2, and Day 4/discharge. | |
Secondary | Oxygenation index (SpO2 /FiO2 ratio). | Oxygenation Index (SpO2 /FiO2 ratio) at Day 1, Day 2, and day 4/discharge compared to baseline. | Oxygenation Index (SpO2 /FiO2 ratio) at Day 1, Day 2, and day 4/discharge | |
Secondary | Patient reported level of dyspnea assessed by Modified Borg Dyspnea Scale. | Patient reported level of dyspnea (assessed by Modified Borg Dyspnea Scale).This is a scale that asks patients to rate the difficulty of their breathing. It starts at number zero (0) where the breathing is causing the patient no difficulty at all, and progresses through to number ten (10) where the patients' breathing difficulty is maximal.
0: Nothing at all; 0.5: Very, very slight (just noticeable); 1: Very slight; 2: Slight; 3: Moderate; 4: Somewhat severe; 5: Severe; 7: Very severe; 9: Very, very severe (almost maximal); 10: Maximal. |
Patient reported level of dyspnea assessed by Modified Borg Dyspnea Scale on Day 0, Day 1, and Day 2. | |
Secondary | Change in patient respiratory status assessed by subjective physician respiratory status evaluation. | Change in patient respiratory status (Respiratory Status Evaluation). Physician observation and evaluation of patient respiratory status at time of enrollment (baseline) and on Day 2 to assess if worse, unchanged, or improved through:
Lung assessment: percussion Lung assessment: Auscultation Cough assessment Secretion assessment oxygenation Work of breathing Other observations: General appearance |
Respiratory status evaluation at time of enrollment and on Day 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06021249 -
Comparing Innovative and Traditional Ventilation Strategies on Atelectasis and Prognosis in Elderly Patients
|
N/A | |
Terminated |
NCT03581474 -
Evaluation of BAL Procedure With Ambu aScope 3 Large in Patients in an ICU Setting
|
N/A | |
Completed |
NCT02523755 -
Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia
|
Phase 4 | |
Completed |
NCT02216006 -
High Fresh Gas Flow After Intubation
|
N/A | |
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT03153592 -
Effects of Mechanical Ventilation Guided by Transpulmonary Pressure on Gas Exchange During Robotic Surgery: a Pilot Study
|
N/A | |
Completed |
NCT03694665 -
Monitoring Lung Recruitment Maneuver in Anesthetized Morbidly Obese
|
N/A | |
Completed |
NCT04506203 -
The Accuracy of Pediatric Air Test as a Non-invasive Atelectasis Diagnostic Tool
|
N/A | |
Not yet recruiting |
NCT06296173 -
Open Lung Protective Extubation Following General Anesthesia
|
N/A | |
Completed |
NCT04006665 -
Role of Lung Ultrasonography in Diagnosing Atelectasis in Robotic Pelvic Surgeries
|
||
Completed |
NCT03614845 -
Evaluation of Effect of Different Ventilator Mods on Atelectasis in Patients Undergoing Laparoscopic Surgery
|
N/A | |
Active, not recruiting |
NCT06075836 -
AI Assisted Detection of Chest X-Rays
|
||
Completed |
NCT01993394 -
Effect of Hyperoxia and Hypergravity on Lung Ventilation and Perfusion
|
N/A | |
Completed |
NCT00671723 -
Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients
|
N/A | |
Completed |
NCT03378752 -
Atelectasis Formation Using HFJV During Stereotactic Solid Organ Ablations
|
||
Completed |
NCT05963945 -
Multi-Reader Retrospective Study Examining Carebot AI CXR 2.0.21-v2.01 Implementation in Everyday Radiology Clinical Practice
|
||
Completed |
NCT03592589 -
Prevention of Atelectasis, Via High Flow Nasal Cannula to Obtain a PEP, During General Anesthesia in Children
|
N/A | |
Completed |
NCT04458623 -
Air Test In Diagnosis Of Postoperative Lung Atelectasis
|
N/A | |
Recruiting |
NCT05710419 -
Effects of Invasive Mechanical Ventilation on the Right Ventricular Function
|